|
1
|
Braunstein M, Rajkumar P, Claus CL,
Vaccarelli G, Moore AJ, Wang D and Anderson MK: HEBAlt enhances the
T-cell potential of fetal myeloid-biased precursors. Int Immunol.
22:963–972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van de Beek D, De Gans J, Spanjaard L,
Weisfelt M, Reitsma JB and Vermeulen M: Clinical features and
prognostic factors in adults with bacterial meningitis. N Engl J
Med. 351:1849–1859. 2004.
|
|
3
|
Harrison LH, Mohan N and Kirkpatrick P:
Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev
Drug Discov. 9:429–430. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khatami A and Pollard AJ: The epidemiology
of meningococcal disease and the impact of vaccines. Expert Rev
Vaccines. 9:285–298. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Águeda S, Campos T and Maia A: Prediction
of bacterial meningitis based on cerebrospinal fluid pleocytosis in
children. Braz J Infect Dis. 17:401–404. 2013.PubMed/NCBI
|
|
6
|
Raymond J: Neisseria meningitidis:
characterisation and epidemiology. Arch Pediatr. 19(Suppl 2):
S55–S60. 2012.(In French).
|
|
7
|
Ferguson LE, Hormann MD, Parks DK and
Yetman RJ: Neisseria meningitidis: presentation, treatment, and
prevention. J Pediatr Health Care. 16:119–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Findlow J, Lowe A, Deane S, Balmer P, van
den Dobbelsteen G, Dawson M, Andrews N and Borrow R: Effect of
sequence variation in meningococcal PorA outer membrane protein on
the effectiveness of a hexavalent PorA outer membrane vesicle
vaccine in toddlers and school children. Vaccine. 23:2623–2627.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van den Dobbelsteen GP, van Dijken HH,
Pillai S and van Alphen L: Immunogenicity of a combination vaccine
containing pneumococcal conjugates and meningococcal PorA OMVs.
Vaccine. 25:2491–2496. 2007.PubMed/NCBI
|
|
10
|
Aaberge IS, Oster P, Helland OS,
Kristoffersen AC, Ypma E, Høiby EA, Feiring B and Nøkleby H:
Combined administration of meningococcal serogroup B outer membrane
vesicle vaccine and conjugated serogroup C vaccine indicated for
prevention of meningococcal disease is safe and immunogenic. Clin
Diagn Lab Immunol. 12:599–605. 2005.
|
|
11
|
Zhou H, Gao Y, Xu L, Li M, Li Q, Li Y,
Liang X, Luo H, Kan B, Xu J and Shao Z: Distribution of serogroups
and sequence types in disease-associated and carrier strains of
Neisseria meningitidis isolated in China between 2003 and
2008. Epidemiol Infect. 140:1296–1303. 2012.PubMed/NCBI
|
|
12
|
Yang L, Shao Z, Zhang X, Xu L, Peng J, Xu
X, Liang X, Qi Y and Jin Q: Genotypic characterization of Neisseria
meningitidis serogroup B strains circulating in China. J Infect.
56:211–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panatto D, Amicizia D, Lai PL and
Gasparini R: Neisseria meningitidis B vaccines. Expert Rev
Vaccines. 10:1337–1351. 2011. View Article : Google Scholar
|
|
14
|
Silva GP, Cruz SC, Cruz AC and Milagres
LG: Short-term and long-term antibody response by mice after
immunization against Neisseria meningitidis B or diphtheria toxoid.
Braz J Med Biol Res. 46:148–153. 2013. View Article : Google Scholar
|
|
15
|
Martin D, Cadieux N, Hamel J and Brodeur
BR: Highly conserved Neisseria meningitidis surface protein confers
protection against experimental infection. J Exp Med.
185:1173–1183. 1997. View Article : Google Scholar
|
|
16
|
Halperin SA, Langley JM, Smith B, Wunderli
P, Kaufman L, Kimura A and Martin D: Phase 1 first-in-human studies
of the reactogenicity and immunogenicity of a recombinant
meningococcal NspA vaccine in healthy adults. Vaccine. 25:450–457.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandeputte-Rutten L, Bos MP, Tommassen J
and Gros P: Crystal structure of Neisserial surface protein A
(NspA), a conserved outer membrane protein with vaccine potential.
J Biol Chem. 278:24825–24830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsolakos N, Lie K, Bolstad K, Maslen S,
Kristiansen PA, Hoiby EA, Wallington A, Vipond C, Skehel M, Tang
CM, Feavers IM, Wedege E and Wheeler JX: Characterization of
meningococcal serogroup B outer membrane vesicle vaccines from
strain 44/76 after growth in different media. Vaccine.
28:3211–3218. 2010. View Article : Google Scholar
|
|
19
|
Zimmer SM and Stephens DS: Serogroup B
meningococcal vaccines. Curr Opin Investig Drugs. 7:733–739.
2006.
|
|
20
|
Tamargo B, Márquez Y, Ramírez W, Cedré B,
Fresno M and Sierra G: New proteoliposome vaccine formulation from
N. meningitidis serogroup B, without aluminum hydroxide,
retains its antimeningococcal protectogenic potential as well as
Th-1 adjuvant capacity. BMC Immunol. 14(Suppl 1):
S122013.PubMed/NCBI
|
|
21
|
Richmond P, Kaczmarski E, Borrow R,
Findlow J, Clark S, McCann R, Hill J, Barker M and Miller E:
Meningococcal C polysaccharide vaccine induces immunologic
hyporesponsiveness in adults that is overcome by meningococcal C
conjugate vaccine. J Infect Dis. 181:761–764. 2000. View Article : Google Scholar
|
|
22
|
Cassataro J, Velikovsky CA, Bruno L,
Estein SM, de la Barrera S, Bowden R, Fossati CA and Giambartolomei
GH: Improved immunogenicity of a vaccination regimen combining a
DNA vaccine encoding Brucella melitensis outer membrane
protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine
Immunol. 14:869–874. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin D, Brodeur BR, Hamel J, Couture F,
de Alwis U, Lian Z, Martin S, Andrews D and Ellis RW: Candidate
Neisseria meningitidis NspA vaccine. J Biotechnol. 83:27–31. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cadieux N, Plante M, Rioux CR, Hamel J,
Brodeur BR and Martin D: Bactericidal and cross-protective
activities of a monoclonal antibody directed against Neisseria
meningitidis NspA outer membrane protein. Infect Immun.
67:4955–4959. 1999.PubMed/NCBI
|
|
25
|
Lewis LA, Ngampasutadol J, Wallace R, Reid
JE, Vogel U and Ram S: The meningococcal vaccine candidate
neisserial surface protein A (NspA) binds to factor H and enhances
meningococcal resistance to complement. PLoS Pathog.
6:e10010272010. View Article : Google Scholar
|
|
26
|
Arenas J, Nijland R, Rodriguez FJ, Bosma
TN and Tommassen J: Involvement of three meningococcal
surface-exposed proteins, the heparin-binding protein NhbA, the
α-peptide of IgA protease and the autotransporter protease NalP, in
initiation of biofilm formation. Mol Microbiol. 87:254–268.
2013.PubMed/NCBI
|
|
27
|
Vaughan AT, Gorringe A, Davenport V,
Williams NA and Heyderman RS: Absence of mucosal immunity in the
human upper respiratory tract to the commensal bacteria Neisseria
lactamica but not pathogenic Neisseria meningitidis during the peak
age of nasopharyngeal carriage. J Immunol. 182:2231–2240. 2009.
View Article : Google Scholar
|
|
28
|
Davenport V, Groves E, Horton RE, Hobbs
CG, Guthrie T, Findlow J, Borrow R, Naess LM, Oster P, Heyderman RS
and Williams NA: Mucosal immunity in healthy adults after
parenteral vaccination with outer-membrane vesicles from
Neisseria meningitidis serogroup B. J Infect Dis.
198:731–740. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trotter CL, Yaro S, Njanpop-Lafourcade BM,
Drabo A, Kroman SS, Idohou RS, Sanou O, Bowen L, Findlow H,
Diagbouga S, Gessner BD, Borrow R and Mueller JE: Seroprevalence of
bactericidal, specific IgG antibodies and incidence of meningitis
due to group A Neisseria meningitidis by age in Burkina Faso
2008. PLoS One. 8:e554862013.PubMed/NCBI
|
|
30
|
Zhao F, Wang S, Zhang X, Gu W, Yu J, Liu
S, Zeng T, Zhang Y and Wu Y: Protective efficacy of a Treponema
pallidum Gpd DNA vaccine vectored by chitosan nanoparticles and
fused with interleukin-2. Can J Microbiol. 58:117–123. 2012.
View Article : Google Scholar
|
|
31
|
Haghi F, Peerayeh SN, Siadat SD and
Montajabiniat M: Cloning, expression and purification of outer
membrane protein PorA of Neisseria meningitidis serogroup B.
J Infect Dev Ctries. 5:856–862. 2011.PubMed/NCBI
|
|
32
|
da Hora VP, Conceição FR, Dellagostin OA
and Doolan DL: Non-toxic derivatives of LT as potent adjuvants.
Vaccine. 29:1538–1544. 2011.PubMed/NCBI
|
|
33
|
Jung DJ, An JH, Kurokawa K, Jung YC, Kim
MJ, Aoyagi Y, Matsushita M, Takahashi S, Lee HS, Takahashi K and
Lee BL: Specific serum Ig recognizing staphylococcal wall teichoic
acid induces complement-mediated opsonophagocytosis against
Staphylococcus aureus. J Immunol. 189:4951–4959. 2012. View Article : Google Scholar
|
|
34
|
Kelly DF and Rappuoli R: Reverse
vaccinology and vaccines for serogroup B Neisseria
meningitidis. Adv Exp Med Biol. 568:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
